SpectraScience announced that they are participating in a licensing agreement with Duke University.
SpectraScience, a medical device company utilizing light technologies to detect and diagnose cancers, announced that they are participating in a licensing agreement with Duke University. The technology covered is around systems and methods for the use of Angle-Resolved Low Coherence Interferometry in the diagnosis of certain cancers.
“We are excited to be working with an institution as prestigious as Duke University to advance medical diagnostics,” said Michael Oliver, president and CEO of SpectraScience. “The intellectual property we have licensed from Duke is the underlying technology for the Oncoscope products we acquired earlier this year. With the potential to develop a product for light-based diagnosis of Barrett’s Esophagus, a precursor to esophageal cancer, we are continuing to broaden our product offerings. Our goal is to be the premier company using light to provide invivo diagnosis of cancer.”
SpectraScience
www.spectrascience.com
